Omega-3

Omega-3

Best for

Raise omega-3 levels

Likely strong benefit for 0–244 weeks · 1 meta-analysis , n=3k

202 papers · 16 claims · 322 outcomes scored · 14 positive

Outcomes

What omega-3 actually does, by outcome

Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.

Outcome Effect Evidence Dose Weeks Rank
Raise omega-3 levels Likely strong benefit
large
35 meta-analyses n=3.0k Meta-analyzed 2.5–9120 mg 0–244 wk #1/6
Build nutrient stores in pregnancy Likely strong benefit
large
1 RCT n=238 200–1000 mg #2/4
Lose body fat Large effect, needs confirmation
large
5 RCTs n=136 3–3900 mg 8–26 wk #8/56
Slow macular degeneration progression Likely strong benefit
large
2 meta-analyses n=— Meta-analyzed 1000 mg 260 wk #2/5
Protect against macular degeneration Large effect, needs confirmation
large
2 meta-analyses n=— Meta-analyzed 1000 mg 260 wk #1/6
Ease dry, gritty eyes Likely benefit
moderate
6 meta-analyses n=6.4k Meta-analyzed 300–3000 mg 8–52 wk #1/3
Improve school results in children Likely benefit
moderate
2 RCTs n=362 600–800 mg 16 wk
Lower triglycerides Proven modest benefit
small
32 meta-analyses n=116k Meta-analyzed 0.3–14000 g 3–183 wk #1/89
Protect vision in retinal disease Faint early signal
small
3 meta-analyses n=5.6k Meta-analyzed 600–3600 mg 208 wk #5/5
Slow cognitive decline in dementia Proven modest benefit
small
6 meta-analyses n=2.7k Meta-analyzed 480–3000 mg 17–156 wk #3/23
Improve omega-3 to omega-6 ratio Likely modest benefit
small
14 meta-analyses n=1.1k Meta-analyzed 2.5–9120 mg 3–56 wk #1/6
Boost overall cognitive performance Barely detectable
trivial
7 meta-analyses n=14k Meta-analyzed 230–4950 mg 26–260 wk #5/21
Strengthen healthy birth weight Proven but unnoticeable
trivial
2 meta-analyses n=8.7k Meta-analyzed 200–1000 mg #6/7
Strengthen your memory Proven but unnoticeable
trivial
11 meta-analyses n=1.5k Meta-analyzed 37–4950 mg 16–156 wk #6/42
Sharpen visual clarity Not enough research
trivial
2 meta-analyses n=5.5k Meta-analyzed
Build thinking skills in children Doesn't appear to help
trivial
3 meta-analyses n=5.5k Meta-analyzed 800 mg

Risk profile

Adverse events and known drug interactions

Safety events

atrial fibrillation severe
Diarrhea severe
Epistaxis (nosebleed) severe
Severe GI events resulting in treatment discontinuation severe
Dyspnea severe
pain in extremity (grade 3, single case reported) severe
pain severe
hemoglobin_decreased severe

Drug interactions

Cyclophosphamide major decreases effect
Acetaminophen major increases toxicity
Lipid Modifying Agents major increases toxicity
Aspirin moderate increases effect
Warfarin moderate additive
Valproic Acid moderate increases effect
Tazobactam moderate increases concentration
Atorvastatin moderate increases concentration
Antithrombotic Agents moderate increases toxicity
Celecoxib moderate additive

Co-studied with

Supplements that share evidence with omega-3

Sources

  1. 1. Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial. (2020)
  2. 2. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. (2009)
  3. 3. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. (2009)
  4. 4. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. (2010)
  5. 5. Incorporation of n-3 PUFA and γ-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. (2011)
  6. 6. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. (2013)
  7. 7. Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults. (2013)
  8. 8. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. (2014)
  9. 9. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder. (2015)
  10. 10. No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial. (2015)

Generated August 14, 2026

Want personalized recommendations?

Show me what works for me